Overview

Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial

Status:
Completed
Trial end date:
2020-05-19
Target enrollment:
Participant gender:
Summary
In this study the investigators want to find out more about the addition of the antibiotic, doxycycline, to standard anti-amyloid therapy in people with amyloidosis. The investigators want to find out whether doxycycline improves the response to standard anti-amyloid therapy and whether it causes any problems (side effects).
Phase:
Phase 2
Details
Lead Sponsor:
Medical College of Wisconsin
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Doxycycline